129 related articles for article (PubMed ID: 29629484)
21. Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies.
Kumar S; Larson DR; Dispenzieri A; Therneau TM; Murray DL; Leif Bergsagel P; Kyle RA; Vincent Rajkumar S
Blood Cancer J; 2019 May; 9(6):49. PubMed ID: 31101803
[TBL] [Abstract][Full Text] [Related]
22. Pathogenesis and progression of monoclonal gammopathy of undetermined significance.
Bladé J; Rosiñol L; Cibeira MT; de Larrea CF
Leukemia; 2008 Sep; 22(9):1651-7. PubMed ID: 18668131
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of Monoclonal Gammopathy in Wild-Type Transthyretin Amyloidosis.
Geller HI; Singh A; Mirto TM; Padera R; Mitchell R; Laubach JP; Falk RH
Mayo Clin Proc; 2017 Dec; 92(12):1800-1805. PubMed ID: 29202938
[TBL] [Abstract][Full Text] [Related]
24. Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians.
Caers J; Vekemans MC; Bries G; Beel K; Delrieu V; Deweweire A; Demuynck H; De Prijck B; De Samblanx H; Kentos A; Meuleman N; Mineur P; Offner F; Vande Broek I; Van Droogenbroeck J; Vande Velde A; Wu KL; Delforge M; Schots R; Doyen C;
Ann Med; 2013 Sep; 45(5-6):413-22. PubMed ID: 23767978
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
26. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study.
Golombick T; Diamond TH; Manoharan A; Ramakrishna R
Am J Hematol; 2012 May; 87(5):455-60. PubMed ID: 22473809
[TBL] [Abstract][Full Text] [Related]
28. Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study.
Kaplan B; Golderman S; Aizenbud B; Esev K; Kukuy O; Leiba M; Livneh A; Ben-Zvi I
Am J Hematol; 2014 Sep; 89(9):882-8. PubMed ID: 24866208
[TBL] [Abstract][Full Text] [Related]
29. [Monoclonal gammopathy of undetermined significance (MGUS) in Mexican mestizos: one institution's experience].
Ruiz-Delgado GJ; Gómez Rangel JD
Gac Med Mex; 2004; 140(4):375-9. PubMed ID: 15456147
[TBL] [Abstract][Full Text] [Related]
30. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.
Katzmann JA; Clark R; Kyle RA; Larson DR; Therneau TM; Melton LJ; Benson JT; Colby CL; Dispenzieri A; Landgren O; Kumar S; Bradwell AR; Cerhan JR; Rajkumar SV
Leukemia; 2013 Jan; 27(1):208-12. PubMed ID: 22781594
[TBL] [Abstract][Full Text] [Related]
31. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Willrich MAV; Murray DL; Kyle RA
Clin Biochem; 2018 Jan; 51():38-47. PubMed ID: 28479151
[TBL] [Abstract][Full Text] [Related]
32. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance.
Rajkumar SV; Kyle RA; Therneau TM; Clark RJ; Bradwell AR; Melton LJ; Larson DR; Plevak MF; Katzmann JA
Br J Haematol; 2004 Nov; 127(3):308-10. PubMed ID: 15491291
[TBL] [Abstract][Full Text] [Related]
33. Epidemiology of Monoclonal Gammopathy of Undetermined Significance (MGUS): The experience from the specialized registry of hematologic malignancies of Basse-Normandie (France).
Cabrera Q; Macro M; Hebert B; Cornet E; Collignon A; Troussard X
Cancer Epidemiol; 2014 Aug; 38(4):354-6. PubMed ID: 24880205
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; Rajkumar SV
Hematol Oncol Clin North Am; 2007 Dec; 21(6):1093-113, ix. PubMed ID: 17996590
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic performances of M-protein tests according to the clinical presentations of kidney disease.
Koo EH; Shin JH; Jang HR; Park HD; Kwon GY; Huh W; Kim DJ; Kim YG; Oh HY; Lee JE
Eur J Intern Med; 2016 Sep; 33():88-92. PubMed ID: 27421913
[TBL] [Abstract][Full Text] [Related]
36. [Retrospective analysis of progression to multiple myeloma or related disorders in 114 patients with monoclonal gammopathy of undetermined significance in a single institute].
Yokota S; Urasaki Y; Nakamura Y; Bessho M
Rinsho Ketsueki; 2012 Mar; 53(3):303-9. PubMed ID: 22499046
[TBL] [Abstract][Full Text] [Related]
37. The incidental monoclonal protein: current approach to management of monoclonal gammopathy of undetermined significance (MGUS).
Madan S; Greipp PR
Blood Rev; 2009 Nov; 23(6):257-65. PubMed ID: 19699016
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and incidence of anemia in the German Heinz Nixdorf Recall Study.
Eisele L; Dürig J; Broecker-Preuss M; Dührsen U; Bokhof B; Erbel R; Moebus S; Jöckel KH;
Ann Hematol; 2013 Jun; 92(6):731-7. PubMed ID: 23430088
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
40. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M
Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
